Novo Nordisk

Business in russia — Scaling back in russia

According to its 20-F annual report (filed with the SEC on 4 February 2026), Novo Nordisk's factory in russia is still operating to supply insulin to patients in russia only; the company maintains supply of medicine for more than 700,000 patients but has ceased the launch of new medications and suspended further clinical investments. This is company-reported information; no court finding of fault exists.

  • subject, 2026-02-04
  • kse, 2025-11-07